scholarly journals Prooxidant Activity of Poria Mushroom Extract on Renal Cell Carcinoma: Potential Therapeutic Strategy

2020 ◽  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Therapeutic Strategy ◽  
Prooxidant Activity ◽  
Mushroom Extract

scholarly journals circAMOTL1L Suppresses Renal Cell Carcinoma Growth by Modulating the miR-92a-2-5p/KLLN Pathway

2021 ◽  
Vol 2021 ◽  
pp. 1-17
Author(s):  
Ling Gao ◽  
Xian Shao ◽  
Qingqing Yue ◽  
Weifei Wu ◽  
Xuejuan Yang ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Therapeutic Strategy ◽  
Underlying Mechanism ◽  
Tumor Stage ◽  
Circular Rnas ◽  
The Novel ◽  
Regulatory Functions

Accumulating evidence indicates that the dysregulation of circular RNAs (circRNAs) contributes to tumor progression; however, the regulatory functions of circRNAs in renal cell carcinoma (RCC) remain largely unknown. In this study, the function and underlying mechanism of circAMOTL1L in RCC progression were explored. qRT-PCR showed the downregulation of circAMOTL1L in RCC tissues and cell lines. The decrease in circAMOTL1L expression correlated with the tumor stage, metastasis, and poor prognosis in patients with RCC. Functional experiments revealed that circAMOTL1L inhibited cell proliferation and increased apoptosis in RCC cells. Subcutaneous implantation with circAMOTL1L-overexpressing cells in nude mice decreased the growth ability of the xenograft tumors. Mechanistically, circAMOTL1L served as a sponge for miR-92a-2-5p in upregulating KLLN (killin, p53-regulated DNA replication inhibitor) expression validated by bioinformatics analysis, oligo pull-down, and luciferase assays. Further, reinforcing the circAMOTL1L–miR-92a-2-5p–KLLN axis greatly reduced the growth of RCC in vivo. Conclusively, our findings demonstrate that circAMOTL1L has an antioncogenic role in RCC growth by modulating the miR-92a-2-5p–KLLN pathway. Thus, targeting the novel circAMOTL1L–miR-92a-2-5p–KLLN regulatory axis might provide a therapeutic strategy for RCC.

Clinical outcome and molecular characterization of patients receiving systemic therapy for metastatic sarcomatoid renal cell carcinoma.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e15084-e15084
Author(s):  
Joann Hsu ◽  
Sumanta Kumar Pal ◽  
Przemyslaw Twardowski ◽  
Courtney Carmichael ◽  
Junmi Saikia ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Targeted Therapies ◽  
Systemic Therapy ◽  
Renal Cell ◽  
Therapeutic Strategy ◽  
Clinicopathologic Characteristics ◽  
Mesenchymal Transition ◽  
Comparison Results ◽  
Significant Difference

e15084 Background: Sarcomatoid metastatic renal cell carcinoma (mRCC) represents an aggressive subset of disease, and a definitive therapeutic strategy is lacking. Methods: From an institutional database including 270 patients with mRCC, we identified 34 patients with documented sarcomatoid features. Within this cohort, we assessed 21 patients who received systemic therapy. Survival was assessed in the overall cohort and in subgroups divided by clinicopathologic characteristics, including the extent of sarcomatoid features, MSKCC risk criteria, and the nature of systemic therapy given. Available tissue from 11 of these patients has been identified for correlative studies to assess markers of epithelial to mesenchymal transition (EMT). Tissue will be obtained from a cohort of patients matched for age and MSKCC risk status (but lacking a sarcomatoid component) for comparison. Results: Of the 21 patients assessed, 2 patients received chemotherapy, 7 patients received immunotherapy, and 12 patients received targeted agents as their first line treatment. Median overall survival (OS) in the overall cohort was 18.0 months (95%CI 6.9-22.0). By MSKCC status, patients with poor-risk disease had a median OS of 4.7 months, as compared to 20.1 months for patients with intermediate-risk disease (HR 0.02, 95%CI 0.003-0.15; P=0.0001). Survival in subgroups stratified by the Heng criteria will be presented at the meeting. There was no significant difference in survival in patients with sarcomatoid predominant disease (>20%) vs non-predominant disease (HR 0.62, 95%CI 0.23-1.65; P=0.34), nor was there a difference amongst patients who received targeted therapies vs non-targeted therapies (HR 1.0, 95%CI 0.61-1.40; P=0.36). Correlative analyses are ongoing, and will be presented at the meeting. Conclusions: As compared to previous retrospective series (Golshayan et al JCO 2009) and prospective trials (Haas et al Med Oncol 2011) assessing patients with sarcomatoid mRCC, the survival in our cohort was substantially prolonged. Further clinical and translational studies are needed to refine current prognostic schema for this disease, and to define the optimal therapeutic strategy.

Abstract 2546: HDAC and Hsp90 inhibition as therapeutic strategy for translocation renal cell carcinoma

2015 ◽  
Author(s):  
Sheng-Yu Ku ◽  
Swathi Ramakrishnan ◽  
Eric Ciamporcero ◽  
Bo Xu ◽  
Gissou Azabdaftari ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Therapeutic Strategy ◽  
Hsp90 Inhibition

Reappraisal of the Role of Bevacizumab in the Therapeutic Strategy in Advanced Renal Cell Carcinoma

2012 ◽  
Vol 10 (3) ◽  
pp. 147-152 ◽  
Author(s):  
Aline Guillot ◽  
Antonin Levy ◽  
Cécile Pacaut ◽  
Olivier Collard ◽  
Christophe Massard ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Therapeutic Strategy ◽  
Advanced Renal Cell Carcinoma

Targeting HIF-2 α in clear cell renal cell carcinoma: A promising therapeutic strategy

2017 ◽  
Vol 111 ◽  
pp. 117-123 ◽  
Author(s):  
Olga Martínez-Sáez ◽  
Pablo Gajate Borau ◽  
Teresa Alonso-Gordoa ◽  
Javier Molina-Cerrillo ◽  
Enrique Grande
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Therapeutic Strategy ◽  
Clear Cell ◽  
Cell Renal Cell Carcinoma

scholarly journals Treatment of Renal Cell Carcinoma with 2-Stage Totalen blocSpondylectomy after Marked Response to Molecular Target Drugs

2013 ◽  
Vol 2013 ◽  
pp. 1-4
Author(s):  
Yasuhiro Inoue ◽  
Hiroshi Takahashi ◽  
Yuichiro Yokoyama ◽  
Yasuaki Iida ◽  
Katsunori Fukutake ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Therapeutic Strategy ◽  
Molecular Target ◽  
Palliative Surgery ◽  
High Rate ◽  
En Bloc ◽  
Primary Disease ◽  
One Year

Metastatic renal cell carcinoma of the bone occurs at a high rate, and the prognosis is poor. In general, totalen blocspondylectomy is considered when there is only one vertebral metastasis and the primary disease is treated. However, palliative surgery is selected when the primary disease is not being treated or metastasis occurs to an important organ. We encountered a patient in whom lung and vertebra metastases were already present at the time of the first examination at our department and the prognosis was considered poor. However, molecular targeted therapy was markedly effective and enabled 2-stage totalen blocspondylectomy. As of one year after totalen blocspondylectomy, the condition has improved to cane gait, and surgery for lung metastasis is planned. Molecular target drugs might markedly change the current therapeutic strategy for renal cell carcinoma.

scholarly journals ADENOCARCINOMA OF COLON AND RENAL CARCINOMA OF CLEAR SYNCHRONIC CELLS: A CASE REPORT

2018 ◽  
Vol 3 (5) ◽  
pp. 35-50
Author(s):  
Morgana Tavares Dantas Sousa ◽  
Antonio Taumaturgo Sampaio Macêdo ◽  
Marco Antônio Bezerra Rolim ◽  
Roberto De Souza Mendonça ◽  
José Carlos Apolonio da Silva ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Therapeutic Strategy ◽  
Renal Carcinoma ◽  
Diagnostic Methods ◽  
Cell Variant ◽  
Genetic And Environmental Factors ◽  
Clear Cell Variant ◽  
Single Approach

This study reported the case of a patient with a diagnosis of colonic and renal synchronic tumors: Moderately differentiated adenocarcinoma of sigmoid and renal carcinoma of the synchronic clear cell variant in a 66-year-old female patient who were surgically resected in a single approach in an Oncology service in the interior of the State of Ceará, Brazil. For data collection, records of the medical record, interview with the patient and the surgeon responsible for the case, photographic record of the diagnostic methods to which the patient was submitted, and literature review were used. It followed all the ethical principles established by law 466/2012. From this study it was concluded that: a) the incidence of colorectal cancer and synchronic renal cell carcinoma ranges from 0.03 to 4.85% in the analyzed literature, b) risk factors for synchronic tumors include genetic and environmental factors; c) renal cell carcinoma is usually diagnosed by performing preoperative tests for staging of abdominal carcinomas. Still, large prospective studies are necessary to define the best therapeutic strategy, however, some authors have confirmed that simultaneous laparoscopic resection of both neoplasms is possible and presents low morbidity and mortality. Keywords: synchronic tumor, colon cancer, renal cancer.

Sign in / Sign up

Export Citation Format

Share Document